TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:02
Alkermes plc. ( ALKS ) https://www.alkermes.com
29.81USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ALKS
6.92%
SPY
32.66%
ALKS
26.80%
SPY
108.59%
ALKS
45.91%
SPY
302.52%
-48.67%
ALKS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4979.02
4365.12
0.77
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
14.94
3.31
3.85
6.63
0.00
11.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
27.70
82.94
25.99
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.7488
24.42
23.54
0.66
Other Earnings and Cash Flow Stats:
Alkermes plc. ( ALKS ) Net Income TTM ($MM) is 333.35
Alkermes plc. ( ALKS ) Operating Income TTM ($MM) is 312.58
Alkermes plc. ( ALKS ) Owners' Earnings Annual ($MM) is 362.82
Alkermes plc. ( ALKS ) Current Price to Owners' Earnings ratio is 13.21
Alkermes plc. ( ALKS ) EBITDA TTM ($MM) is 352.81
Alkermes plc. ( ALKS ) EBITDA Margin is 25.99%
Capital Allocation:
Alkermes plc. ( ALKS ) has paid 0.00 dividends per share and bought back 4.878 million shares in the past 12 months
Alkermes plc. ( ALKS ) has reduced its debt by 90.003 million USD in the last 12 months
Capital Structure:
Alkermes plc. ( ALKS ) Interest-bearing Debt ($MM) as of last quarter is 294
Alkermes plc. ( ALKS ) Annual Working Capital Investments ($MM) are -167
Alkermes plc. ( ALKS ) Book Value ($MM) as of last quarter is 1292
Alkermes plc. ( ALKS ) Debt/Capital as of last quarter is 22%
Other Balance Sheet Stats:
Alkermes plc. ( ALKS ) has 396 million in cash on hand as of last quarter
Alkermes plc. ( ALKS ) has 453 million of liabilities due within 12 months, and long term debt 288 as of last quarter
Alkermes plc. ( ALKS ) has 167 common shares outstanding as of last quarter
Alkermes plc. ( ALKS ) has 0 million USD of preferred stock value
Academic Scores:
Alkermes plc. ( ALKS ) Altman Z-Score is 4.60 as of last quarter
Alkermes plc. ( ALKS ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
Alkermes plc. ( ALKS ) largest shareholder is owning shares at 0.00 ($MM) value
Hopkinson Craig C.(an insider) Sold 61151 shares of Alkermes plc. ( ALKS ) for the amount of $1961406.09 on 2024-12-09
1.31% of Alkermes plc. ( ALKS ) is held by insiders, and 112.23% is held by institutions
Alkermes plc. ( ALKS ) went public on 1991-07-16
Other Alkermes plc. ( ALKS ) financial metrics:
FCF:308.03
Unlevered Free Cash Flow:485.01
EPS:2.21
Operating Margin:27.70
Gross Profit Margin:82.94
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:28.60
Beta:0.66
Buffet's Owners Earnings:362.82
Price to Owner's Earnings:13.21
About Alkermes plc. ( ALKS ) :
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA/ XEPLION for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA, TREVICTA, and HAFYERA/BYANNLI to treat schizophrenia; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.